Generic diabetes pill put to the test against Brand-Name drug
NCT ID NCT07266779
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked if a new generic pill for type 2 diabetes (ertugliflozin/metformin) works the same as the brand-name drug (Segluromet). Thirty-six healthy adults took a single dose of each pill in random order. The goal was to see if the body absorbs both drugs at similar levels, which would mean the generic is a safe and effective alternative.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Veeda Clinical Research Limited
Gujrat, Gujarat, 384205, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- Blood test could predict who faces rapid kidney decline in diabetes
- Blood test may predict kidney decline in diabetes — a large trial investigates
- Hormone clue may unmask kidney danger in diabetes
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?